Inicio › Carcinoma urotelial (de células de transición) › Tennessee › Nashville
Ensayos clínicos de Carcinoma urotelial (de células de transición) en Nashville, TN
23 estudios para Carcinoma urotelial (de células de transición) buscan participantes en centros de Nashville y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
ReclutandoFase 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ReclutandoFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
ReclutandoFase 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
ReclutandoFase 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
ReclutandoEstudio observacional
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
ReclutandoFase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- y 9 más
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
ReclutandoFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
ReclutandoFase 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
ReclutandoFase 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
ReclutandoFase 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
ReclutandoFase 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
ReclutandoFase 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
ReclutandoFase 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
ReclutandoFase 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
ReclutandoFase 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Reclutando
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
ReclutandoFase 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Nashville
Ensayos de Carcinoma urotelial (de células de transición) en otras ciudades
- New York City, NY22 estudios
- Houston, TX19 estudios
- Dallas, TX18 estudios
- Edison, NJ18 estudios
- Los Angeles, CA17 estudios
- Queens, NY15 estudios
- Chicago, IL14 estudios
- Arlington, VA12 estudios
- Boston, MA11 estudios
- San Antonio, TX11 estudios
- Austin, TX10 estudios
- Orange, CA10 estudios
Otros estudios en Nashville
- Cáncer de pulmón de células no pequeñas97 estudios
- Cáncer de seno81 estudios
- Cáncer metastásico70 estudios
- Cáncer del colon y del recto69 estudios
- Cáncer (todos los tipos)65 estudios
- Cáncer de ovario49 estudios
- Cáncer de próstata43 estudios
- Cáncer de pulmón40 estudios
- Carcinoma de células escamosas de cabeza y cuello39 estudios
- Cáncer de páncreas39 estudios
- Cáncer de endometrio38 estudios
- Melanoma33 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.